Epirubicin and Docetaxel in the Treatment of Patients With Metastatic Breast Cancer
Phase 2
Terminated
- Conditions
- Breast Cancer
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2011-05-03
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 90
- Registration Number
- NCT00193024
Weekly Topotecan in Patients Treated for Metastatic Colorectal Cancer
Phase 2
Completed
- Conditions
- Colon Cancer
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2011-05-03
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 40
- Registration Number
- NCT00193167
- Locations
- 🇺🇸
Tennessee Oncology, Nashville, Tennessee, United States
Chemotherapy With or Without Surgical Resection in Locally Advanced Esophageal Cancer
Phase 2
Completed
- Conditions
- Esophagus Cancer
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2011-05-03
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 200
- Registration Number
- NCT00193141
Arsenic Trioxide in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase 2
Completed
- Conditions
- Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2011-05-03
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 41
- Registration Number
- NCT00193518
- Locations
- 🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
Adjuvant Docetaxel and Estramustine Phosphate for High Risk Localized Prostate Cancer
Phase 2
Completed
- Conditions
- Prostate Cancer
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2011-05-03
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 30
- Registration Number
- NCT00193271
- Locations
- 🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
Weekly Docetaxel and CMF in the Adjuvant Treatment of Elderly Women With High-Risk Breast Cancer
Phase 3
Completed
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2011-05-03
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 150
- Registration Number
- NCT00193011
Topotecan Plus Paclitaxel and Carboplatin in the Initial Treatment of Advanced Ovarian and Primary Peritoneal Carcinoma
Phase 2
Completed
- Conditions
- Ovary Cancer
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2011-05-03
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 50
- Registration Number
- NCT00193297
Ifosfamide/Carboplatin/Etoposide/Rituxan Followed by Zevalin in Relapsed/Refractory Intermediate Grade B-Cell Lymphoma
Phase 2
Completed
- Conditions
- Non-Hodgkins Lymphoma
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2011-05-03
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 40
- Registration Number
- NCT00193505
- Locations
- 🇺🇸
Tennessee Oncology, PLLC, Nashville, Tennessee, United States
Topotecan in Combination With Docetaxel in Refractory and/or Advanced Solid Tumors
Phase 1
Completed
- Conditions
- Cancer
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2009-01-23
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 20
- Registration Number
- NCT00193570
Bevacizumab and Erlotinib in the Treatment of Patients With Carcinoma of Unknown Primary Site
Phase 2
Completed
- Conditions
- Neoplasms, Unknown Primary
- First Posted Date
- 2005-09-19
- Last Posted Date
- 2010-09-17
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 50
- Registration Number
- NCT00193622
© Copyright 2025. All Rights Reserved by MedPath